Merck and Moderna maintain a longstanding 50/50 co-development partnership on their personalized mRNA cancer vaccine intismeran autogene, recently bolstered by positive Phase 3 INTerpath-001 results in August 2026 that met recurrence-free and distant metastasis-free survival endpoints in resected melanoma. This clinical success has driven sharp share-price gains for both companies without triggering any merger or acquisition signals, as management prioritizes advancing the joint program through additional trials in lung, bladder, and kidney cancers alongside potential regulatory filings. Analyst commentary has floated hypothetical acquisition scenarios to consolidate economics ahead of Keytruda patent pressures, yet no deal terms, regulatory reviews, or stakeholder actions point to an announced transaction by year-end. The market-implied odds reflect this continued arm's-length collaboration amid strong pipeline momentum rather than corporate combination.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourOui
10% chance
NOUVEAU
NOUVEAU
31 déc. 2026
Oui
10% chance
NOUVEAU
NOUVEAU
31 déc. 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a longstanding 50/50 co-development partnership on their personalized mRNA cancer vaccine intismeran autogene, recently bolstered by positive Phase 3 INTerpath-001 results in August 2026 that met recurrence-free and distant metastasis-free survival endpoints in resected melanoma. This clinical success has driven sharp share-price gains for both companies without triggering any merger or acquisition signals, as management prioritizes advancing the joint program through additional trials in lung, bladder, and kidney cancers alongside potential regulatory filings. Analyst commentary has floated hypothetical acquisition scenarios to consolidate economics ahead of Keytruda patent pressures, yet no deal terms, regulatory reviews, or stakeholder actions point to an announced transaction by year-end. The market-implied odds reflect this continued arm's-length collaboration amid strong pipeline momentum rather than corporate combination.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Marché ouvert : Aug 19, 2026, 3:58 PM ET
Volume
$458Date de fin
1 janv. 2027Marché ouvert
Aug 19, 2026, 3:58 PM ETRésolveur
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a longstanding 50/50 co-development partnership on their personalized mRNA cancer vaccine intismeran autogene, recently bolstered by positive Phase 3 INTerpath-001 results in August 2026 that met recurrence-free and distant metastasis-free survival endpoints in resected melanoma. This clinical success has driven sharp share-price gains for both companies without triggering any merger or acquisition signals, as management prioritizes advancing the joint program through additional trials in lung, bladder, and kidney cancers alongside potential regulatory filings. Analyst commentary has floated hypothetical acquisition scenarios to consolidate economics ahead of Keytruda patent pressures, yet no deal terms, regulatory reviews, or stakeholder actions point to an announced transaction by year-end. The market-implied odds reflect this continued arm's-length collaboration amid strong pipeline momentum rather than corporate combination.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volume
$458Date de fin
1 janv. 2027Marché ouvert
Aug 19, 2026, 3:58 PM ETRésolveur
0x65070BE91...Merck and Moderna maintain a longstanding 50/50 co-development partnership on their personalized mRNA cancer vaccine intismeran autogene, recently bolstered by positive Phase 3 INTerpath-001 results in August 2026 that met recurrence-free and distant metastasis-free survival endpoints in resected melanoma. This clinical success has driven sharp share-price gains for both companies without triggering any merger or acquisition signals, as management prioritizes advancing the joint program through additional trials in lung, bladder, and kidney cancers alongside potential regulatory filings. Analyst commentary has floated hypothetical acquisition scenarios to consolidate economics ahead of Keytruda patent pressures, yet no deal terms, regulatory reviews, or stakeholder actions point to an announced transaction by year-end. The market-implied odds reflect this continued arm's-length collaboration amid strong pipeline momentum rather than corporate combination.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes